Nuage Therapeutics

What Nuage Therapeutics does

Nuage Therapeutics is a preclinical biotechnology company headquartered at Barcelona Science Park (Parc Científic de Barcelona), Spain, founded in 2021 as a spin-off from the Institute for Research in Biomedicine (IRB Barcelona). The company is developing small-molecule drugs that target intrinsically disordered proteins (IDPs) — a class of proteins, including oncogenic transcription factors, that constitute roughly 40% of the human proteome and have historically been considered undruggable due to their lack of stable structure. The platform exploits the natural tendency of IDPs to transiently self-assemble into higher-order structures, capturing these transiently druggable conformations for covalent small-molecule binding.

The core technology stack consists of four components: the Target Discovery Algorithm (TDA), an IDR knowledge vault that prioritizes undruggable targets; the IDR reconstitution methodology that induces binding-enabled transient structural ordering; a proprietary C-Assay and biophysical assay suite enabling high-throughput screening of covalent binding events; and a sustained covalent inhibition mechanism that blocks protein-protein interactions essential to disease progression. The pipeline targets three oncogenic transcription factor programs: ASCL1 (small-cell lung cancer, SCLC-A) with lead candidate NTX-A, KLF5 (digestive system cancers), and an undisclosed target. The company has been supported by IRB Barcelona, EMBL Barcelona, VHIO, and CNIO as research collaborators.

Nuage operates a preclinical asset-development business model with no commercialized products and no disclosed revenue. Its intended revenue mechanics are pharmaceutical licensing deals, co-development agreements, and downstream royalties on commercialized assets. To date, the company has funded operations through a €12 million seed round (June 2023, co-led by Sofinnova Partners and Asabys Partners) and a stack of non-dilutive grants (Eurostars, EIT Health, Torres Quevedo, and €2.7 million from the Spanish State Research Agency), with the explicit objective of advancing NTX-A into clinical-phase-ready data. The go-to-market strategy will depend on pharma partnerships for clinical development and commercialization.

Name

Nuage Therapeutics

Legal name

Nuage Therapeutics SL

Website

https://www.nuagetx.com/

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Development and Licensing: As a preclinical biotech company, Nuage Therapeutics is developing a pipeline of oncology drugs targeting intrinsically disordered proteins. Revenue would be generated through licensing deals with pharmaceutical partners, co-development agreements, and eventual product commercialization.

Distribution channels1 record

Marketing channels5 records

Core offering

Nuage Therapeutics is a preclinical biotech company that develops first-in-class small molecule drugs targeting intrinsically disordered proteins (IDPs), with a primary focus on oncogenic transcription factors driving aggressive cancers. The company operates an integrated discovery platform that reconstitutes transiently druggable conformations of disordered proteins, enabling high-throughput screening and covalent inhibitor design against targets previously considered undruggable. Its lead candidate, NTX-A, targets the ASCL1 transcription factor for small-cell lung cancer (SCLC-A).

Product overview

Nuage Therapeutics operates as an integrated biotech platform company with two core pillars: a proprietary drug discovery platform and a therapeutic pipeline. The platform consists of the Target Discovery Algorithm (TDA) for target prioritization and the C-Assay/biophysical assay suite for screening and characterization. The pipeline programs target oncogenic transcription factors including ASCL1 (SCLC-A), KLF5 (digestive cancers), and an undisclosed target. Lead drug candidate NTX-A targets ASCL1-driven small-cell lung cancer. All programs leverage the platform's ability to transiently order intrinsically disordered proteins for small molecule binding.

Differentiator

Problem solved

Functional benefit

Products and services

• IDP Drug Discovery Platform Integrated proprietary drug discovery platform that reconstitutes intrinsically disordered proteins into transiently druggable conformations, enabling small molecule targeting of previously undruggable oncogenic transcription factors. Used internally by Nuage and validated against multiple IDPs.
• SCLC-A Program (ASCL1 Program) Discovery and development program for first-in-class covalent inhibitors targeting ASCL1 (Achaete-Scute Family bHLH Transcription Factor 1), a master regulator of neuroendocrine differentiation and key oncogenic driver in small-cell lung cancer (SCLC-A).
• KLF5 Program (Multiple Digestive System Cancers) Exploratory program for targeted therapeutics against the KLF5 transcription factor in digestive system cancers where it drives proliferation and metastasis.
• Undisclosed Target Program Early-stage research program targeting an undisclosed oncogenic transcription factor for multiple indications, identified via Nuage's Target Discovery Algorithm.
• NTX-A Lead preclinical drug candidate developed by Nuage to target the ASCL1 protein for the most common subtype of small-cell lung cancer (SCLC-A). Being advanced toward clinical phase with consortium partners CNIO, EMBL Barcelona, and VHIO.
• Target Discovery Algorithm (TDA) Proprietary target prioritisation tool functioning as an IDR knowledge vault that systematically identifies, evaluates, and prioritises previously undruggable targets with the highest therapeutic potential.
• C-Assay and Biophysical Assay Suite Proprietary biophysics toolbox leveraging unique IDR conformational state know-how to enable high-throughput screening and deep characterisation of selective covalent small molecule binding events against intrinsically disordered protein targets.

Quantifiable outcome

• Successfully developed NTX-A, a pioneering drug candidate targeting ASCL1 for small-cell lung cancer treatment
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• CNIO (Spanish National Cancer Research Centre)coreStrategic or Co-development Partner · 2 December 2025Research collaboration partner in the €2.7 million AEI-funded project for developing NTX-A drug candidate against small-cell lung cancer (SCLC-A).
• EMBL Barcelona (European Molecular Biology Laboratory)coreStrategic or Co-development Partner · 2 December 2025Research collaborator providing organoid development expertise. Talya Dayton's group leads development of patient-derived tumor organoids (PDTOs) for drug testing.
• VHIO (Vall d'Hebron Institute of Oncology)coreStrategic or Co-development Partner · 2 December 2025Research partner in drug development consortium. Dr. Marcos Malumbres leads investigation of tumor evolution and resistance mechanisms to ASCL1 inhibitors.
• AseBio (Spanish BioIndustry Association)minorOthers · 26 June 2025Nuage joined AseBio, the Spanish BioIndustry Association. Stuart Hughes interviewed about company's mission and the biotech ecosystem in Spain.
• IRB Barcelona (Institute for Research in Biomedicine)coreStrategic or Co-development Partner · 1 January 2024Nuage Therapeutics is a spin-off from IRB Barcelona. Co-founders Xavier Salvatella and research teams continue collaboration.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nuagetx

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuage Therapeutics